Eli Lilly announces agreement to acquire Disarm Therapeutics

▴ Eli Lilly announces agreement to acquire Disarm Therapeutics
Eli Lilly successfully develop and commercialize new medicines resulting from the acquisition

Eli Lilly and Company announced a definitive agreement to acquire Disarm Therapeutics, a privately-held biotechnology company creating a new class of disease-modifying therapeutics for patients with axonal degeneration. Disarm has discovered novel, potent SARM1 inhibitors and is advancing them in preclinical development, with the goal of delivering breakthrough treatments to patients with peripheral neuropathy and other neurological diseases such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis.

Axonal degeneration is a common, yet unaddressed, pathology in a broad range of neurological diseases and is known to cause severe sensory, motor, and cognitive symptoms. Disarm's scientific founders, Dr Jeffrey Milbrandt and Dr Aaron DiAntonio of Washington University School of Medicine in St Louis, discovered that the SARM1 protein is a central driver of axonal degeneration. Disarm's SARM1 inhibitors are designed to directly prevent the loss of axons.

Under the terms of the agreement, Lilly will acquire Disarm for an upfront payment of $135.0 million. Disarm equityholders may be eligible for up to $1.225 billion in additional future payments for potential development, regulatory and commercial milestones should Lilly successfully develop and commercialize new medicines resulting from the acquisition.

"Lilly continues to seek medicines to treat the debilitating pain and loss of function associated with nerve damage," said Mark Mintun, M.D., vice president of pain and neurodegeneration research at Lilly. "The scientific team at Disarm discovered an important and highly promising approach to combat axonal degeneration. We will move quickly to develop their SARM1 inhibitors into potential medicines for peripheral neuropathy and neurological diseases, such as ALS and multiple sclerosis."

"Disarm's innovative approach to treating axonal degeneration holds tremendous promise for addressing a wide spectrum of neurological diseases, and we have made significant strides toward enabling potentially transformative therapies," said Alvin Shih, M.D., Chief Executive Officer of Disarm. "Lilly is ideally suited to advance this exciting new approach to treating axonal degeneration, and we look forward to seeing patients benefit from the work that Disarm initiated." Disarm was founded by Atlas Venture, Dr Milbrandt and DiAntonio of Washington University School of Medicine in St. Louis, and Atlas Entrepreneurs-in-Residence Dr Rajesh Devraj and Dr Raul Krauss. Lightstone Ventures and AbbVie Ventures co-invested with Atlas to support the foundational work at Disarm.

Tags : #EliLilly #LatestNewsonEliLilly16thOct #DisarmTherapeutics #LatestNewsonDisarmTherapeutics16thOct #LatestPharmaAcquisitionNews16thOct #LatestPharmaNews16thOct #DrJeffreyMilbrandt #DrAaronDiAntonio #MarkMintunofEliLilly

About the Author


Team Medicircle

Related Stories

Loading Please wait...
-Advertisements-


Trending Now

COVID-19 recovery rate reaches close to 91%October 29, 2020
Fasenra eliminated oral corticosteroid use in a majority of OCS-dependent patients with asthma October 29, 2020
Dupixent reports safe administrations for young patients with moderate-to-severe atopic dermatitisOctober 29, 2020
Reddy's partners with Department of Biotechnology for Sputnik V vaccine clinical trials in IndiaOctober 29, 2020
Study shows new estimates of breast cancer risks associated with HRTOctober 29, 2020
France will go back into a nationwide lockdown starting this weekOctober 29, 2020
CStone and LegoChem Biosciences enter into global licensing agreementOctober 29, 2020
Santen and Aerie signed exclusive agreement for Rhopressa and Rocklatan in Japan and Several Other Asian CountriesOctober 29, 2020
Dr. Harsh Vardhan reviews COVID-19 preparedness and measures for ensuring COVID Appropriate Behaviour in Tamil NaduOctober 29, 2020
China: Xinjiang’s Kashgar under restrictions with 183 corona virus casesOctober 29, 2020
Takeda collaborates with Moderna to supply COVID-19 vaccine in JapanOctober 29, 2020
Cancer Genetics, Inc. Increases Previously Announced Bought Deal to $3.0 MillionOctober 29, 2020
Karnataka reports 3,146 new cases of COVID-19October 29, 2020
1,504 new cases of COVID-19 reported in TelanganaOctober 29, 2020
Health Minister Dr Harsh Vardhan digitally inaugurates Radio diagnosis Facilities at AIIMS, BathindaOctober 29, 2020
Covid breaks another record, over 2 million cases reported in just one week: WHO October 29, 2020
Bengaluru makes it mandatory for drivers to wear masks even if they are alone October 29, 2020
Union Health Ministry’s telemedicine service, eSanjeevani, completes 6 lakh tele-consultations October 29, 2020
Recovery rate of COVID patients in Delhi stands at 90.33 pct October 29, 2020
Covid-19 recovery rate crosses 90 % in country; Active caseload falls below 8% October 29, 2020